62774-57-6

Basic information

• Product Name: Hydrazinecarboxamide, N-(4-methylphenyl)-
• Synonyms: 4-methyl phenyl semicarbazide;???(4-methylphenyl)amine;N-(4-methylphenyl)hydrazinecarboxamide;4-(p-Tolyl)semicarbazid;N-p-tolylhydrazinecarboamide;4-p-tolyl-semicarbazide;p-Toluidinoformyl-hydrazin;Hydrazinecarboxamide,N-(4-methylphenyl)
• CAS NO: 62774-57-6
• Molecular Formula: C8H11N3O
• Molecular Weight: 165.195
• Mol File: 62774-57-6.mol
• Article Data: 20

Chemical Properties

• CAS DataBase Reference: Hydrazinecarboxamide, N-(4-methylphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Hydrazinecarboxamide, N-(4-methylphenyl)-(62774-57-6)
• EPA Substance Registry System: Hydrazinecarboxamide, N-(4-methylphenyl)-(62774-57-6)

Safety Data

• Hazardous Substances Data: 62774-57-6(Hazardous Substances Data)

Upstream product

• 622-51-5 p-tolylurea 
• 2492-30-0 acetophenone semicarbazone 
• 106-49-0 p-toluidine 
• 109091-32-9 3-(4-methylphenyl)-5-benzylidene-2,4-thiazolidinedione 
• 540-23-8 p-toluidine hydrochloride 
• 622-58-2 p-Tolylisocyanate 
• 33275-26-2 N-(4-methylphenyl)-O-phenyl carbamate 
• 5255-66-3 ethyl p-tolylcarbamate 
• 51028-33-2 C₈H₈ClNO 

Downstream Products

• 1221255-84-0 N-(4-methylphenyl)-2-(quinolin-2-ylmethylene)hydrazinecarboamide 
• 93192-57-5 4-p-tolyl-2,4-dihydro-[1,2,4]triazol-3-one 
• 1356965-16-6 2-[(1E)-1-(1,3-benzodioxol-5-yl)-4,4-dimethylpent-1-en-3-ylidene]-N-(4-methylphenyl)hydrazinecarboxamide 
• 1356965-24-6 (5RS)-5-(benzo[d][1,3]dioxol-5-yl)-3-tert-butyl-N-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carboxamide 
• 1402599-01-2 1-(3-benzyl-6-fluorothiochroman-4-ylidene)-4-(4-methylphenyl)semicarbazide 
• 1402598-97-3 1-(3-benzyl-6-chlorothiochroman-4-ylidene)-4-(4-methylphenyl)semicarbazide 
• 1289575-96-7 C₁₆H₁₄N₄O₂ 

Relevant articles and documents

Design, synthesis, and biological activity of novel semicarbazones as potent Ryanodine receptor1 inhibitors of Alzheimer's disease

Ryanodine receptors (RyRs) are important ligand-gated Ca2+ channels; their excessive activation leads to Ca2+ leakage in the sarcoplasmic reticulum that may cause neurological diseases. In this study, three series of novel potent RyR1 inhibitors based on dantrolene and bearing semicarbazone and imidazolyl moieties were designed and synthesized, and their biological activity was evaluated. Using a single-cell calcium imaging method, the calcium overload inhibitory activities of 26 target compounds were tested in the R614C cell line, using dantrolene as a positive control. The preliminary investigation showed that compound 12a suppressed Ca2+ release as evidenced by store overload-induced Ca2+release (SOICR) (31.5 ± 0.1%, 77.2 ± 0.1%, 93.7 ± 0.2%) at 0.1 μM, 3 μM and 10 μM, respectively. Docking simulation results showed that compound 12a could bind at the active site of the RyR1 protein. The Morris water-maze test showed that compound 12a significantly improved the cognitive behavior of AD-model mice. Further studies on the structural optimization of this series of derivatives are currently underway in our laboratory.

Synthesis, cytotoxicity, and in vivo antitumor activity study of parthenolide semicarbazones and thiosemicarbazones

Parthenolide is an important sesquiterpene lactone with potent anticancer activities. In order to further improve its biological activity, a series of parthenolide semicarbazone or thiosemicarbazone derivatives was synthesized and evaluated for their anti

Design and synthesis of novel N-(4-(Pyridin-2-yloxy)benzylidene)-4-[4-(substituted)phenyl]semicarbazides as potential anticonvulsant agents

A new series of N-(4-(pyridin-2-yloxy)benzylidene)-4-[4-(substituted)phenyl]semicarbazides (PSSD1-8) were designed and synthesized keeping in view the structural requirement of pharmacophore and evaluated for their possible anticonvulsant activity. All the derivatives were synthesized by the given scheme and reaction process was monitored by thin layer chromatography. The structure of synthesized derivatives was confirmed by FT-IR, 1H NMR, mass spectroscopy and elemental analysis. The anticonvulsant activity was established after intraperitoneal administration in MES and scMET seizure models. The most active compound of the series was 1-(4-(pyridin-2-yloxy)-benzylidene)-4-p-tolylsemicarbazide (PSSD5). A molecular docking study was carried out in order to assess the interaction and binding modes with target receptor/enzyme. Titled compounds were found to strongly bind to human gamma-aminobutyric acid receptor (GABAAR-β3). A computational study was also carried to predict the pharmacokinetic properties of the synthesized compounds.